Immunology beats cancer: A blueprint for successful translation

Drew M. Pardoll

doi:10.1038/ni.2392

Immunology beats cancer: A blueprint for successful translation

Drew M. Pardoll

School of Medicine

Research output: Contribution to journal › Review article › peer-review

120 Scopus citations

Abstract

Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.

Original language	English (US)
Pages (from-to)	1129-1132
Number of pages	4
Journal	Nature Immunology
Volume	13
Issue number	12
DOIs	https://doi.org/10.1038/ni.2392
State	Published - Dec 2012

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1038/ni.2392

Cite this

@article{ec3ce39f4a8640e381737281607a9e19,

title = "Immunology beats cancer: A blueprint for successful translation",

abstract = "Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.",

author = "Pardoll, \{Drew M.\}",

year = "2012",

month = dec,

doi = "10.1038/ni.2392",

language = "English (US)",

volume = "13",

pages = "1129--1132",

journal = "Nature Immunology",

issn = "1529-2908",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - Immunology beats cancer

T2 - A blueprint for successful translation

AU - Pardoll, Drew M.

PY - 2012/12

Y1 - 2012/12

N2 - Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.

AB - Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.

UR - https://www.scopus.com/pages/publications/84869380716

UR - https://www.scopus.com/pages/publications/84869380716#tab=citedBy

U2 - 10.1038/ni.2392

DO - 10.1038/ni.2392

M3 - Review article

C2 - 23160205

AN - SCOPUS:84869380716

SN - 1529-2908

VL - 13

SP - 1129

EP - 1132

JO - Nature Immunology

JF - Nature Immunology

IS - 12

ER -

Immunology beats cancer: A blueprint for successful translation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this